ABT-869 ( Linifanib ) ( CAS: 796967-16-3 )

Linifanib (ABT-869) is a structurally novel, potent inhibitor of receptor

tyrosine kinases (RTK), vascular endothelial growth factor (VEGF) andplatelet-derived

growth factor (PDGF) with IC50 of 0.2, 2, 4, and 7 nM for human endothelial cells, 

PDGF receptor beta (PDGFR-β), KDR, and colony stimulating factor 1 receptor 

(CSF-1R), respectively. It has much less activity (IC50s > 1 μM) against unrelated

RTKs, soluble tyrosine kinases, or serine/threonine kinases. In vivo linifanib is

effective orally in mechanism-based murine models of VEGF-induced uterine

edema (ED50 = 0.5 mg/kg) and corneal angiogenesis (>50%inhibition, 15 mg/kg).